

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS P O Box 1450 Alexandria, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/560,336	04/26/2007	Claudia Woppmann	051058-1000	2542
8471.7 7590 11/18/2009 Nixon Peabody LLP 401 9th Street N.W.			EXAMINER	
			ZARA, JANE J	
Suite 900 Washington, DC 20004			ART UNIT	PAPER NUMBER
···tomington, z	20001		1635	
			MAIL DATE	DELIVERY MODE
			11/13/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

### Application No. Applicant(s) 10/560,336 WOPPMANN ET AL. Office Action Summary Art Unit Examiner Jane Zara 1635 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 7-1-09. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 44-74 is/are pending in the application. 4a) Of the above claim(s) 57-69 and 71-74 is/are withdrawn from consideration. 5) Claim(s) \_\_\_\_\_ is/are allowed. 6) Claim(s) 44-56 and 70 is/are rejected. 7) Claim(s) \_\_\_\_\_ is/are objected to. 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abevance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some \* c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). \* See the attached detailed Office action for a list of the certified copies not received. Attachment(s)

1) Notice of References Cited (PTO-892)

3) Information Disclosure Statement(s) (PTC/G5/08)
Paper No(s)/Mail Date \_\_\_\_\_\_

Notice of Draftsperson's Patent Drawing Review (PTO-948)

Interview Summary (PTO-413)
 Paper No(s)/Mail Date.

6) Other:

Notice of Informal Patent Application

#### DETAILED ACTION

This Office action is in response to the communication filed 7-1-09.

Claims 44-74 are pending in the instant application.

### Election/Restrictions

This application contains claims 57-69, 71-74, drawn to an invention nonelected with traverse in the reply filed on 1-15-09. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144)

See MPEP § 821.01.

## Response to Arguments and Amendments

### Withdrawn Rejections

Any rejections not repeated in this Office action are hereby withdrawn.

### Maintained Rejections

### Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 44-56, 70 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement for the reasons of record set forth in the Office action mailed 4-1-09, and as set forth below. The claim(s) contains subject

Art Unit: 1635

matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Applicant's arguments filed 7-1-09 have been fully considered but they are not fully persuasive. Applicant argues that adequate written description has been provided for the expansive genus of inhibitory compounds claimed. Applicant points to Example 5, which provides three different dsRNA molecules comprising the motifs claimed with regard to the GC base pair contents and positioning within the siRNA molecules, as well as with respect to the overhangs and their nucleotide compositions. Applicant is correct that the prior art does not render the claimed motifs obvious. Applicant is correct that these motifs (with respect to the GC base pairs, positions, and overhangs) have been adequately described.

But, contrary to Applicant's assertions, the comparisons between these different dsRNA molecules comprising the various motifs instantly claimed all comprise fully complementary dsRNA – fully complementary with respect to the antisense strand and the target region, and fully complementary with respect to this antisense targeting region and its complementary (sense) strand on the siRNA molecule. Example 6 does not aid in fulfilling the required written description because this merely teaches that an siRNA comprising more GC base pairs has a higher Tm than one which has less GC base pairs, which is predictable.

The optimization and presumed utility of the claimed motif(s), therefore, are based on these fully complementary sequences described above, and exemplified using

Art Unit: 1635

the Bcl20 target gene in Example 5. But adequate description has not been provided, at the time of filing, of these advantages in siRNA that are <u>not</u> fully complementary to the target gene sequence, and which antisense and sense strands are <u>not</u> complementary with respect to each other. Therefore, it appears that adequate written description has been provided for the claimed <u>motifs with respect to siRNA comprising at least 19 nucleobases that are fully complementary to the target gene sequence (e.g. as claimed in claim 50), <u>but also including the added limitation that the sense and antisense strands additionally share full complementary with respect to this target region.</u></u>

For these reasons, the instant rejection is maintained.

#### Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Art Unit: 1635

Certain papers related to this application may be submitted to Art Unit 1635 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. '1.6(d)). The official fax telephone number for the Group is 571-273-8300. NOTE: If Applicant does submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jane Zara whose telephone number is (571) 272-0765. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Tracy Vivlemore, can be reached on (571) 272-2914. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Jane Zara 10-23-09

Page 6

Art Unit: 1635

/Jane Zara/

Primary Examiner, Art Unit 1635